Status:
COMPLETED
Evaluating the Symbicort Turbuhaler (Formoterol/Budesonide) Maintenance and Reliever Therapy for Asthma in Daily Practice
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Brief Summary
We want to evaluate efficacy of Symbicort® Turbuhaler® (formoterol/budesonide) therapy for asthma in real life conditions. For this purpose we will include both patients that are treated with Symbicor...
Eligibility Criteria
Inclusion
- patients diagnosed with persistent asthma treated with Symbicort® Turbuhaler® in line with its label
- non-pregnant females
- existing maintenance only treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg, 160 μg/4,5 μg or 320 μg/9 μg for at least 1 month
- existing SMART treatment with Symbicort® Turbuhaler® 80 μg/4,5 μg or 160 μg /4,5 μg for at least 1 month
Exclusion
- patients not being treated with Symbicort® Turbuhaler®
- patients treated with Symbicort® Turbuhaler® for COPD
Key Trial Info
Start Date :
April 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
April 1 2009
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00782314
Start Date
April 1 2008
End Date
April 1 2009
Last Update
July 24 2009
Active Locations (24)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Celje, Celje, Slovenia
2
Research Site
Dvorec Sela, Dvorec Sela, Slovenia
3
Research Site
Grosuplje, Grosuplje, Slovenia
4
Research Site
Idrija, Idrija, Slovenia